43,857 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by SG Americas Securities LLC

Key Points

• SG Americas Securities LLC bought a new position of 43,857 shares (~$1.77M) in Terns Pharmaceuticals during Q4, adding to heavy institutional interest that leaves the company with 98.26% institutional ownership.
• Insiders have been net sellers recently — 98,857 shares (~$3.85M) sold in the last three months (including CEO Amy Burroughs' sale of 14,583 shares), and insiders now own about 1.5% of the stock.
• Analyst sentiment is mixed but the consensus is a "Hold" with a $56.30 price target, and the company recently reported quarterly EPS of -$0.24, beating estimates of -$0.30.

SG Americas Securities LLC bought a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 43,857 shares of the company's stock, valued at approximately $1,772,000.

Several other large investors have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd increased its holdings in shares of Terns Pharmaceuticals by 237.2% in the third quarter. Dynamic Technology Lab Private Ltd now owns 66,576 shares of the company's stock worth $500,000 after purchasing an additional 46,831 shares during the period. AlphaQuest LLC grew its position in Terns Pharmaceuticals by 9,088,200.0% during the third quarter. AlphaQuest LLC now owns 90,883 shares of the company's stock worth $683,000 after buying an additional 90,882 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Terns Pharmaceuticals by 90.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 682,708 shares of the company's stock worth $5,127,000 after acquiring an additional 324,502 shares during the last quarter. Commodore Capital LP bought a new position in Terns Pharmaceuticals in the 3rd quarter worth about $42,807,000. Finally, Integral Health Asset Management LLC raised its holdings in shares of Terns Pharmaceuticals by 35.7% in the 3rd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the company's stock valued at $7,134,000 after acquiring an additional 250,000 shares in the last quarter. 98.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TERN has been the subject of several recent analyst reports. Barclays reissued an "equal weight" rating and set a $53.00 price objective (down from $56.00) on shares of Terns Pharmaceuticals in a report on Monday, March 30th. Wall Street Zen lowered shares of Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Weiss Ratings reissued a "sell (e+)" rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th. Leerink Partners assumed coverage on shares of Terns Pharmaceuticals in a research report on Monday, February 9th. They set an "outperform" rating and a $58.00 price objective on the stock. Finally, Oppenheimer lifted their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an "outperform" rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $56.30.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, insider Emil Kuriakose sold 942 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total value of $49,690.50. Following the completion of the sale, the insider owned 105,673 shares of the company's stock, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares of the company's stock, valued at $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 98,857 shares of company stock valued at $3,850,896 over the last three months. 1.50% of the stock is currently owned by insiders.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ TERN opened at $52.72 on Monday. The stock has a market capitalization of $6.08 billion, a P/E ratio of -51.18 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a one year low of $1.87 and a one year high of $53.19. The firm's 50 day simple moving average is $42.96 and its two-hundred day simple moving average is $30.97.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, equities analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.

Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.